The EFNB1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphocyte cell line, designed to disrupt the EFNB1 gene encoding the ephrin-B1 ligand. This loss-of-function model enables systematic investigation of ephrin-B1-dependent signaling without relying on pharmacological inhibition or RNA interference, providing a stable genetic background for functional studies.
Raji cells are a well-characterized malignant B lymphocyte line derived from a patient with Burkitt’s lymphoma, an aggressive B-cell malignancy. These cells are Epstein-Barr virus (EBV)-positive and grow in suspension, maintaining key features of transformed B cells. Their robust proliferation, well-defined signaling networks, and relevance to lymphoma biology make them a widely used host for gene-editing approaches aimed at dissecting molecular mechanisms underlying B-cell lymphomagenesis and therapeutic response.
Ephrin-B1 is a transmembrane ligand that engages EphB receptor tyrosine kinases (EphB1, EphB2, EphB3) to trigger bidirectional signaling: forward signaling through EphB kinases and reverse signaling via ephrin-B1 intracellular motifs. Ephrin-B1 is regulated by transcription factors such as HOXA9 and post-transcriptionally by the miR-200 family. Downstream, ephrin-B1 modulates Src family kinases, RhoA and Rac1 GTPases, focal adhesion kinase (FAK), and integrin-mediated adhesion, often in conjunction with PDZ domain adaptor proteins like GRIP1 and clathrin-associated complexes. These components link ephrin-B1 to cytoskeletal reorganization, cell migration, and adhesion dynamics.
In the context of Raji B lymphoma cells, EFNB1 knockout disrupts EphB-ephrin bidirectional communication, which is likely to alter key processes such as cell-cell adhesion, repulsion, and migration??functions implicated in lymphoma niche interactions and dissemination. Given the involvement of ephrin-B1 in cancers such as B-cell lymphoma, glioma, and breast cancer, this knockout model is particularly valuable for dissecting how ephrin-B1 contributes to tumor cell behavior within the microenvironment and for evaluating its role in pathways like MAPK/ERK and Rho GTPase signaling that are frequently dysregulated in malignancy.
The EFNB1 Knockout Raji Polyclonal Cells support a wide range of experimental applications, including functional studies of ephrin-B1 in B-cell lymphoma, investigation of Eph/ephrin signaling in tumor?Cstromal interactions, and drug sensitivity screening. Representative assays include Western blotting to confirm ephrin-B1 loss, flow cytometry for adhesion molecule profiling, migration and invasion assays, co-immunoprecipitation to assess EphB-ephrin complex formation, and phospho-signaling analyses to map downstream pathway activation. For further information on this model, please contact Ascent Research.
